Search Results

ALZPROTECT is thrilled to announce that it has received favorable feedback from both the American and European authorities regarding the regulatory path for advancing the clinical development of Ezeprogind/AZP2006 for patients with PSP.

Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces that the United States Patent and Trademark Office has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind in the treatment of tauopathies.

ALZPROTECT announced the recruitment of the first 5 patients to participate in its phase 2a clinical trial with its drug candidate AZP2006 in Progressive Supranuclear Palsy, an orphan disease for which the company has been granted with the “orphan drug” status by the Food and Drug Administration and European Medicines Agency.

AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer’s disease and Progressive Supranuclear Palsy (PSP), announced today the successful completion of the latest phase 1 study regarding the effect of food intake for its drug candidate AZP2006.

ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer’s disease, today announced that PAREXEL Biotech, a new division of PAREXEL International Corporation, has been selected to perform the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain.

The rising incidences of progressive Supranuclear palsy worldwide are a key factor aiding in expansion of the global progressive Supranuclear palsy treatment market.

The rising incidences of progressive Supranuclear palsy worldwide are a key factor aiding in expansion of the global progressive Supranuclear palsy treatment market.